Form 4: Ginkgo Bioworks CFO Mark Dmytruk Acquires 1.1 Million Restricted Stock Units

Ginkgo Bioworks CFO Mark Dmytruk was granted 1,100,000 Restricted Stock Units (RSUs) that vest monthly over four years, as reported in a Form 4 filing with the SEC.

Summary

• Mark E. Dmytruk, CFO of Ginkgo Bioworks Holdings, Inc., acquired 1,100,000 Restricted Stock Units (RSUs) on March 7, 2024.
• Each RSU represents a contingent right to receive one share of Ginkgo Bioworks' Class A Common Stock.
• The RSUs vest in 48 equal monthly installments starting on April 1, 2024.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The grant of RSUs is a standard practice and indicates confidence in the company's future. It also aligns the CFO's interests with those of the shareholders.

Positives

• The grant of RSUs to the CFO aligns his interests with those of the shareholders, incentivizing him to drive long-term value creation.

Future Outlook

The vesting schedule of the RSUs suggests a commitment from the CFO to remain with the company for at least the next four years.

Industry Context

Grants of restricted stock units are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Stakeholder Impact

• Shareholders may view the RSU grant positively as it aligns management's interests with long-term value creation.
• Employees may see this as a sign of stability and commitment from the CFO.

Key Dates